Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Fast Track designation granted to one-time intravitreal gene therapy for geographic atrophy
➤ FDA clears IND for Stargardt gene therapy to move forward into a Phase 1/2 clinical trial
➤ BLA submission for retinitis pigmentosa gene therapy begins
➤ First patient dosed in Phase 1/2 trial evaluating NK therapy
➤ Enrollment complete in Phase 2b trial for PCED therapy
➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events
➤ Positive results in Phase 1 trial for geographic atrophy cell-based therapy
➤ Enrollment complete for Phase 3 DME drop trials
➤ Enrollment complete in study for hydrogel retinal sealant
➤ First patient dosed in Phase 2 trial studying oral diabetic retinopathy therapy
➤ Regenerative Medicine Advanced Therapy designation granted to gene therapy candidate for X-linked retinoschisis
➤ ASCRS news and events
➤ Study: long-term efficacy of uveoscleral outflow enhancement for glaucoma
➤ FDA grants expanded indication for fluocinolone acetonide intravitreal implant
➤ First patient dosed in Phase 1/2 gene therapy trial targeting Stargardt disease
➤ Merger complete
➤ ASCRS news and events
➤ FDA approves new viscoelastic system
➤ Expanded label approved for geographic atrophy treatment
➤ Biologics application accepted for aflibercept biosimilar
➤ Update on gene therapy program
➤ ASCRS news and events
➤ NDA submitted for epithelium-on crosslinking therapy
➤ Positive results in Phase 2 trial for first-in-class therapy for acute optic neuritis
➤ Study: long-term, real-world findings evaluating standalone canaloplasty and trabeculotomy
➤ Phase 1b study evaluating sozinibercept for DME published
➤ Phase 2 study for topical dry AMD therapy begins
➤ FDA clears IND for gene therapy targeting Stargardt disease
➤ ASCRS news and events
➤ FDA clears device for MGD treatment
➤ Significant investments made in whole-eye transplant research
➤ Enrollment completed early in Phase 3 trial for novel glaucoma drop
➤ Studies make progress with gene and mRNA-based therapies for retinal conditions
➤ ASCRS news and events
➤ Topline Phase 3 results for sublingual, opioid-free sedation
➤ Phase 1 results for non-surgical cell therapy for corneal edema
➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients
➤ Update on Phase 3 study evaluating treatment for progressive myopia
➤ FDA to review NDA for first-in-class dry eye treatment
➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform
➤ ASCRS news and events
➤ Investigational drug-eluting contact lens for glaucoma sees positive results
➤ First clinical-stage RNA-targeting therapy for nAMD
➤ PDUFA data extended for BLA for treatment of macular telangiectasia
➤ Three rare disease designations granted to investigational gene therapy treatments
➤ Partnership and acquisition news
➤ ASCRS news and events
➤ Positive topline Phase 3 confirmatory trial results for transepithelial crosslinking
➤ 18-month data from first-in-human drug-eluting IOL
➤ New Phase 2 findings for investigational geographic atrophy treatment
➤ Study: long-term, low-dose antiviral treatment reduces risk for HZO patients
➤ Acquisition news
➤ ASCRS news and events
